163 related articles for article (PubMed ID: 25652906)
1. Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
Nishiyama N; Takahashi S; Mizuno T; Uehara T; Hashimoto J; Kurimura Y; Masumori N
Int J Clin Oncol; 2015 Oct; 20(5):1012-7. PubMed ID: 25652906
[TBL] [Abstract][Full Text] [Related]
2. [Significance of Procalcitonin Measurement in Cases with Febrile Condition during Chemotherapy for Urological Cancer].
Kurimura Y; Takahashi S; Hiyama Y; Uehara T; Ichihara K; Hashimoto J; Nishiyama N; Kitamura H; Masumori N
Hinyokika Kiyo; 2015 Apr; 61(4):141-5. PubMed ID: 26037672
[TBL] [Abstract][Full Text] [Related]
3. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
[TBL] [Abstract][Full Text] [Related]
4. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
[TBL] [Abstract][Full Text] [Related]
5. Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care.
Pettit N; Boadu D; Bischof JJ
Am J Emerg Med; 2021 Dec; 50():5-9. PubMed ID: 34265732
[TBL] [Abstract][Full Text] [Related]
6. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
Ahn S; Lee YS; Lim KS; Lee JL
Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
[TBL] [Abstract][Full Text] [Related]
7. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
8. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
[TBL] [Abstract][Full Text] [Related]
9. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
11. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
Pherwani N; Ghayad JM; Holle LM; Karpiuk EL
Am J Health Syst Pharm; 2015 Apr; 72(8):619-31. PubMed ID: 25825185
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of Levofloxacin Hydrate in Febrile Neutropenia for Outpatient Chemotherapy].
Inagaki M; Sato J; Nihei S; Kashiwaba M; Kudo K
Gan To Kagaku Ryoho; 2016 May; 43(5):593-6. PubMed ID: 27210089
[TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
[TBL] [Abstract][Full Text] [Related]
14. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
Nguyen M; Jacobson T; Torres J; Wann A
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for refractory febrile neutropenia in urological chemotherapy.
Yasufuku T; Shigemura K; Tanaka K; Arakawa S; Miyake H; Fujisawa M
J Infect Chemother; 2013 Apr; 19(2):211-6. PubMed ID: 23011233
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
Combariza JF; Lombana M; Pino LE; Arango M
Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
[TBL] [Abstract][Full Text] [Related]
17. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
[TBL] [Abstract][Full Text] [Related]
18. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
19. [Initial management of febrile neutropenia].
Badertscher L; Damak H; Mercier L; Décosterd D
Rev Med Suisse; 2016 Aug; 12(526):1321-1325. PubMed ID: 28671776
[TBL] [Abstract][Full Text] [Related]
20. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
